Matthew W. Rosinack

Matthew W. Rosinack

Interim Principal Financial Officer and Principal Accounting OfficeratIovance Biotherapeutics· In the 2025 proxy

Pay in FY2025Iovance Biotherapeutics stock -63.1% the same year

Matthew W. Rosinack was paid $782.5K in FY2025 (Dec). Iovance Biotherapeutics stock fell 63.1% that year.

Pay$100 in the stock at the end of FY24 → $37
Pay is from the Summary Compensation Table of each Iovance Biotherapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Iovance BiotherapeuticsPublic company · 1 yr
    • Interim Principal Financial Officer and Principal Accounting Officer2025 – Present · 1 yrStock in role +98%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?